SUNPHARMA · Healthcare
Sun Pharmaceutical Industries Ltd. reported revenue of ₹14,478 cr for July to September 2025, +8.9% on the year and +4.5% on the quarter. It is the highest quarterly revenue in the last 10 quarters on record. Over the last four quarters revenue comes to ₹54,963 cr, +9.3% on the four before.
Operating profit (EBITDA) was ₹4,527 cr, a margin of 31.3%, +163 bps on the year and +21 bps on the quarter. It is the widest margin of the last 8 quarters (range 25.3% to 31.3%). Operating costs grew +6.4% against revenue growth of +8.9%, so more of each rupee of sales reached operating profit.
Net profit was ₹3,125 cr, +2.9% on the year and +36.3% on the quarter, with earnings per share of ₹13.00. Profit before other income, one-offs and tax grew faster, at +14.0%; other income, one-offs or tax held the headline back. The tax rate was 25% against an average of 18% over the previous 8 quarters, which weighed on profit this quarter. Profit over the last four quarters totals ₹10,485 cr, −5.7% on the four before.
On earnings per share of ₹43.56 over the last four quarters, the stock at ₹1,754.30 trades at 40.3 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹12,192 cr | ₹12,381 cr | ₹11,983 cr | ₹12,653 cr | ₹13,291 cr | ₹13,675 cr | ₹12,959 cr | ₹13,851 cr | ₹14,478 cr | ₹15,521 cr | ₹14,612 cr | ₹15,300 cr |
| YoY | — | — | — | +6% | +9% | +10% | +8% | +9% | +9% | +13% | +13% | +10% |
| EBITDA margin | 26.1% | 28.1% | 25.3% | 28.5% | 29.6% | 29.3% | 28.7% | 31.1% | 31.3% | 31.9% | 27.1% | 28.9% |
| Other income, % of PBT | 11% | 6% | 18% | 16% | 10% | 4% | 8% | −11% | 11% | 2% | 13% | 13% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 14% | 14% | 5% | 16% | 16% | 16% | 34% | 27% | 25% | 20% | 23% | 29% |
| Net profit | ₹2,385 cr | ₹2,561 cr | ₹2,659 cr | ₹2,861 cr | ₹3,037 cr | ₹2,913 cr | ₹2,154 cr | ₹2,293 cr | ₹3,125 cr | ₹3,381 cr | ₹2,710 cr | ₹2,901 cr |
| YoY | — | — | — | +43% | +27% | +14% | −19% | −20% | +3% | +16% | +26% | +27% |
| Core profit YoY | — | — | — | +11% | +30% | +18% | +30% | +22% | +14% | +24% | +3% | +1% |
| EPS | ₹9.90 | ₹10.52 | ₹11.06 | ₹11.82 | ₹12.67 | ₹12.10 | ₹8.96 | ₹9.50 | ₹13.00 | ₹14.04 | ₹11.31 | ₹12.06 |
| Flags | · | · | 1 | 1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 1 | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Sun Pharmaceutical Industries Ltd. reported revenue of ₹14,478 cr (+8.9% on the year) and net profit of ₹3,125 cr (+2.9% on the year) for July to September 2025.
Profit before other income, exceptional items and tax moved +14.0% on the year, against +2.9% for reported profit.
None of the 7 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.